G Stiegler

Summary

Affiliation: University of Natural Resources and Applied Life Sciences
Country: Austria

Publications

  1. ncbi request reprint A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1
    G Stiegler
    Institute of Applied Microbiology, University of Agricultural Sciences, A 1190 Vienna, Austria
    AIDS Res Hum Retroviruses 17:1757-65. 2001
  2. ncbi request reprint Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation
    Gabriela Stiegler
    Institute of Applied Microbiology, University of Agricultural Sciences, Muthgasse, Vienna, Austria
    AIDS 16:2019-25. 2002
  3. ncbi request reprint Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection
    Gabriela Stiegler
    Institute of Applied Microbiology, Vienna, Austria
    J Antimicrob Chemother 51:757-9. 2003
  4. pmc Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors
    Peter Rusert
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 79:8454-69. 2005
  5. ncbi request reprint HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies
    Sabine Nakowitsch
    Institute of Applied Microbiology, University of Natural Resources and Applied Life Sciences, Vienna, Austria
    AIDS 19:1957-66. 2005
  6. pmc Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5)
    Beda Joos
    University Hospital Zurich, Infectious Diseases and Hospital Epidemiology, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Antimicrob Agents Chemother 50:1773-9. 2006
  7. ncbi request reprint GMP production of liposomes--a new industrial approach
    Andreas Wagner
    Polymun Scientific Immunbiologische Forschung GmbH, Vienna, Austria
    J Liposome Res 16:311-9. 2006
  8. ncbi request reprint Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques
    Flavia Ferrantelli
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Virology 358:69-78. 2007
  9. ncbi request reprint Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures
    Markus Sack
    Institute of Molecular Biotechnology, RTWH Aachen University, Worringerweg 1, 52074 Aachen, Germany
    FASEB J 21:1655-64. 2007
  10. pmc In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10
    Amapola Manrique
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 81:8793-808. 2007

Collaborators

Detail Information

Publications35

  1. ncbi request reprint A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1
    G Stiegler
    Institute of Applied Microbiology, University of Agricultural Sciences, A 1190 Vienna, Austria
    AIDS Res Hum Retroviruses 17:1757-65. 2001
    ..Moreover, our results suggest that 4E10 should be further investigated for passive anti-HIV immunotherapy...
  2. ncbi request reprint Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation
    Gabriela Stiegler
    Institute of Applied Microbiology, University of Agricultural Sciences, Muthgasse, Vienna, Austria
    AIDS 16:2019-25. 2002
    ..However, the antiviral effects of antibody treatment have not been fully analyzed in this first clinical trial...
  3. ncbi request reprint Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection
    Gabriela Stiegler
    Institute of Applied Microbiology, Vienna, Austria
    J Antimicrob Chemother 51:757-9. 2003
  4. pmc Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors
    Peter Rusert
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 79:8454-69. 2005
    ..Activities of these MAbs correlated significantly with each other, suggesting that common features of the viral envelope modulate their potencies...
  5. ncbi request reprint HIV-1 mutants escaping neutralization by the human antibodies 2F5, 2G12, and 4E10: in vitro experiments versus clinical studies
    Sabine Nakowitsch
    Institute of Applied Microbiology, University of Natural Resources and Applied Life Sciences, Vienna, Austria
    AIDS 19:1957-66. 2005
    ..Although they have been shown to prevent de novo infection in vivo, their potential for treatment of chronic infection is less clear. One major obstacle may be the emergence of resistant viruses during mAb treatment...
  6. pmc Long-term multiple-dose pharmacokinetics of human monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5)
    Beda Joos
    University Hospital Zurich, Infectious Diseases and Hospital Epidemiology, Ramistrasse 100, CH 8091 Zurich, Switzerland
    Antimicrob Agents Chemother 50:1773-9. 2006
    ..Further studies examining tissue concentrations to explain the differential in vivo activity of the anti-gp120 antibody compared with those of the two anti-gp41 antibodies are warranted...
  7. ncbi request reprint GMP production of liposomes--a new industrial approach
    Andreas Wagner
    Polymun Scientific Immunbiologische Forschung GmbH, Vienna, Austria
    J Liposome Res 16:311-9. 2006
    ....
  8. ncbi request reprint Time dependence of protective post-exposure prophylaxis with human monoclonal antibodies against pathogenic SHIV challenge in newborn macaques
    Flavia Ferrantelli
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Virology 358:69-78. 2007
    ..Taken together with our results from other PEP studies, these data show that the success of passive immunization depends on the nmAb potency/dose and the time window between virus exposure and start of immunotherapy...
  9. ncbi request reprint Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures
    Markus Sack
    Institute of Molecular Biotechnology, RTWH Aachen University, Worringerweg 1, 52074 Aachen, Germany
    FASEB J 21:1655-64. 2007
    ..This highlights important issues raised by the use of plant systems to produce human biologics...
  10. pmc In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10
    Amapola Manrique
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 81:8793-808. 2007
    ..This remarkable vulnerability of the virus to interference within the MPER calls for a further evaluation of the safety and efficacy of MPER-targeting therapeutic and vaccination strategies...
  11. pmc Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection
    Saurabh Mehandru
    Aaron Diamond AIDS Research Center, 455 First Avenue, 7th Floor, New York, NY 10016, USA
    J Virol 81:11016-31. 2007
    ..Though safe, the use of MAbs generally delayed, but did not prevent, virologic rebound. Consideration should be given to further pilot studies with alternative combinations of MAbs and perhaps additional novel treatment modalities...
  12. ncbi request reprint One step membrane incorporation of viral antigens as a vaccine candidate against HIV
    Andreas Wagner
    Polymun Scientific, Immunbiologische Forschung GmbH, Vienna, Austria
    J Liposome Res 17:139-54. 2007
    ..We examined encapsulation efficiency, membrane protein conformation and immunogenicity of this possible liposomal vaccine candidate, which can be produced in GMP-compliant quality with the described technique...
  13. pmc In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 82:1591-9. 2008
    ..Equally, this raises hopes that a preventive vaccine could become effective at comparatively lower neutralizing antibody titers...
  14. ncbi request reprint Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data
    Brigitta Vcelar
    Polymun Scientific, Vienna bImmunology Outpatient Clinic, Vienna, Austria
    AIDS 21:2161-70. 2007
    ..The broadly neutralizing recombinant human HIV-1 antibodies 4E10, 2F5 and Igh1b12 are reported to have autoreactive potential, which is significant for HIV-1 vaccine development and passive immunotherapy using these antibodies...
  15. pmc Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked
    Michael Huber
    Division of Infectious Diseases, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    J Virol 82:3834-42. 2008
    ..In summary, our data support the notion that the in vivo activities of 2G12, 2F5, and 4E10 are likely due to direct neutralization or Fc receptor-mediated mechanisms such as phagocytosis and antibody-dependent cellular cytotoxicity...
  16. pmc Cost-effective production of a vaginal protein microbicide to prevent HIV transmission
    Koreen Ramessar
    Departament de Produccio Vegetal i Ciencia Forestal, Universitat de Lleida, Avenida Alcalde Rovira Roure, 191, Lleida, 25198, Spain
    Proc Natl Acad Sci U S A 105:3727-32. 2008
    ..We conclude that this protein production system may provide a means to achieve microbicide ingredient manufacture at costs that would allow product introduction and manufacture in the developing world...
  17. ncbi request reprint Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
    Alexandra Trkola
    Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
    Nat Med 11:615-22. 2005
    ....
  18. ncbi request reprint Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
    Barton F Haynes
    Duke University School of Medicine, Durham, NC 27710, USA
    Science 308:1906-8. 2005
    ..These results may have important implications for generating effective neutralizing antibody responses by using HIV-1 vaccines...
  19. ncbi request reprint Anti-idiotypic antibody Ab2/3H6 mimics the epitope of the neutralizing anti-HIV-1 monoclonal antibody 2F5
    Renate E Kunert
    Institute of Applied Microbiology, University of Agricultural Sciences, Muthgasse 18, A 1190 Vienna, Austria
    AIDS 16:667-8. 2002
    ..Ab2/3H6 Fab fragments were capable of inducing neutralizing immune and 2F5-specific responses in B6D2F1 mice applying a simple prime-boost regimen of immunization...
  20. ncbi request reprint Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques
    Flavia Ferrantelli
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA
    AIDS 17:301-9. 2003
    ..The majority of infants infected through maternal transmission acquire the virus during birth or postpartum through breastfeeding: mucosal exposure is considered to be a major route of infection...
  21. pmc Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12
    Susanne Wolbank
    Institute of Applied Microbiology, University of Agriculture, A 1190 Vienna, Austria
    J Virol 77:4095-103. 2003
    ....
  22. ncbi request reprint Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B
    Moiz Kitabwalla
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    AIDS Res Hum Retroviruses 19:125-31. 2003
    ..We and others also showed neutralization of primary HIV clade B strains. Together, our data show that the quadruple combination of mAbs effectively neutralized primary HIV clade A, B, C, and D isolates...
  23. pmc Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies
    John R Mascola
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 77:10348-56. 2003
    ..These data suggest that although effector T cells can limit viral replication, they are not able to assist humoral immunity to prevent the establishment of initial infection...
  24. ncbi request reprint Potent cross-group neutralization of primary human immunodeficiency virus isolates with monoclonal antibodies--implications for acquired immunodeficiency syndrome vaccine
    Flavia Ferrantelli
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, and Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    J Infect Dis 189:71-4. 2004
    ..The in vitro cross-group neutralization shown here underscores the broad potential of these nMAbs against divergent virus variants and the relevance of their epitopes in the design of acquired immunodeficiency syndrome vaccines...
  25. pmc Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination
    Lei Zhang
    Department of Haematology, Prince of Wales Hospital and Centre for Vascular Research, University of New South Wales, Kensington, New South Wales 2052, Australia
    J Virol 78:5520-2. 2004
    ..By contrast, reduction in peak viral load later in infection prevents CD4 depletion and contributes to long-term viral control...
  26. ncbi request reprint Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies
    Flavia Ferrantelli
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Infect Dis 189:2167-73. 2004
    ..These data are important for designing clinical trials in human neonates and have general implications for AIDS vaccine development, as the epitopes recognized by the 3 nMAbs are conserved among diverse primary isolates...
  27. ncbi request reprint Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody
    Renate Kunert
    Institute of Applied Microbiology, University of Natural Resources and Applied Life Sciences, A 1190 Vienna, Austria
    AIDS Res Hum Retroviruses 20:755-62. 2004
    ..The antiviral activity could be greatly enhanced by change of IgG(3) to IgG(1). In contrast, the IgM isotype almost completely lost its neutralizing potential...
  28. pmc Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
    James M Binley
    IMM2, Department of Immunology, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, USA
    J Virol 78:13232-52. 2004
    ..As well as the significance for vaccine design, our data have implications for passive-immunization studies in countries where clade C viruses are common, given that only MAbs b12 and 4E10 were effective against viruses from this clade...
  29. pmc Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10
    Saurabh Mehandru
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Floor, New York, NY 10016, USA
    J Virol 78:14039-42. 2004
    ..We propose that the induction of 4E10-like antibodies should be a priority in designing immunogens to prevent HIV-1 infection...
  30. ncbi request reprint Trimeric membrane-anchored gp41 inhibits HIV membrane fusion
    Oliver Lenz
    European Molecular Biology Laboratory EMBL, 6, rue Jules Horowitz, 38042 Grenoble, France
    J Biol Chem 280:4095-101. 2005
    ..Our data suggest that liposome-anchored gp41ctm exerts its inhibitory action outside of the initial fusion contact site, and its implications for the fusion reaction are discussed...
  31. pmc Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1
    Michael B Zwick
    Department of Immunology IMM 2, The Scripps Research Institute, 10550 North Torrey Pines Rd, La Jolla, CA 92037, USA
    J Virol 79:1252-61. 2005
    ..Neutralization experiments showing synergy between and T20 and 4E10 against HIV-1 are also presented. The data presented may aid in the design of antigens that better present the MPER of gp41 to the immune system...
  32. doi request reprint Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure
    Richard Strasser
    Institute of Applied Genetics and Cell Biology, University of Natural Resources and Applied Life Sciences, Muthgasse 18, 1190 Vienna, Austria
    Plant Biotechnol J 6:392-402. 2008
    ..The generated RNAi lines were stable, viable and did not show any obvious phenotype, thus providing a robust tool for the production of therapeutically relevant glycoproteins in plants with a humanized N-glycan structure...
  33. ncbi request reprint Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of HIV-1 envelope glycoprotein-mediated fusion
    Antony S Dimitrov
    Center for Cancer Research Nanobiology Program, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, USA
    Biochemistry 46:1398-401. 2007
    ..Addition of C34 did not counteract the loss of antibody binding, suggesting that changes in exposure of MPER occur independently of six-helix bundle formation...
  34. ncbi request reprint Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans
    Thomas Rademacher
    Institute for Molecular Biotechnology, Biology VII, RWTH Aachen, Worringerweg 1, 52074 Aachen, Germany
    Plant Biotechnol J 6:189-201. 2008
    ....
  35. pmc Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment
    Christian Kittel
    Institute of Applied Microbiology, Muthgasse 18B, A 1190 Vienna, Austria
    J Virol 79:10672-7. 2005
    ..These results indicate that influenza viruses could be engineered for the expression of biologically active molecules such as cytokines for immune modulation purposes...